Literature DB >> 25487618

Lycorine induces programmed necrosis in the multiple myeloma cell line ARH-77.

Yuhao Luo1, Mridul Roy, Xiaojuan Xiao, Shuming Sun, Long Liang, Huiyong Chen, Yin Fu, Yang Sun, Min Zhu, Mao Ye, Jing Liu.   

Abstract

Lycorine, a natural alkaloid, has been widely reported to possess potential efficacy against cancer. However, the anti-multiple myeloma mechanism of lycorine is not fully understood. In this study, the results demonstrated that lycorine is effective against multiple myeloma cell line ARH-77 via inducing programmed necrosis. The mechanisms of lycorine on the multiple myeloma cell line ARH-77 are associated with G1 phase cell cycle arrest, mitochondrial dysfunction, reactive oxygen species (ROS) generation, ATP depletion, and DNA damage. Our results elucidate the new mechanism of lycorine against multiple myeloma.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25487618     DOI： 10.1007/s13277-014-2924-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  66 in total

1.  Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis.

Authors:  Vladislav Temkin; Qiquan Huang; Hongtao Liu; Hiroyuki Osada; Richard M Pope
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

2.  Effects of lycorine on HL-60 cells via arresting cell cycle and inducing apoptosis.

Authors:  Jing Liu; Wei-Xin Hu; Li-Fang He; Mao Ye; Yan Li
Journal:  FEBS Lett       Date:  2004-12-17       Impact factor: 4.124

Review 3.  Proteolytic mechanisms in necrotic cell death and neurodegeneration.

Authors:  Marta Artal-Sanz; Nektarios Tavernarakis
Journal:  FEBS Lett       Date:  2005-04-02       Impact factor: 4.124

4.  Lycorine induces apoptosis and down-regulation of Mcl-1 in human leukemia cells.

Authors:  Xiao-shan Liu; Jikai Jiang; Xiao-yang Jiao; Ying-e Wu; Jing-hua Lin; Ying-mu Cai
Journal:  Cancer Lett       Date:  2008-09-30       Impact factor: 8.679

Review 5.  The roles of therapy-induced autophagy and necrosis in cancer treatment.

Authors:  Ravi K Amaravadi; Craig B Thompson
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

6.  Human ALKBH7 is required for alkylation and oxidation-induced programmed necrosis.

Authors:  Dragony Fu; Jennifer J Jordan; Leona D Samson
Journal:  Genes Dev       Date:  2013-05-10       Impact factor: 11.361

7.  PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration.

Authors:  Ganta Vijay Chaitanya; Alexander J Steven; Phanithi Prakash Babu
Journal:  Cell Commun Signal       Date:  2010-12-22       Impact factor: 5.712

8.  Treatment of lycorine on SCID mice model with human APL cells.

Authors:  J Liu; Y Li; L J Tang; G P Zhang; W X Hu
Journal:  Biomed Pharmacother       Date:  2007-02-12       Impact factor: 6.529

9.  An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.

Authors:  Erik A Bey; Melissa S Bentle; Kathryn E Reinicke; Ying Dong; Chin-Rang Yang; Luc Girard; John D Minna; William G Bornmann; Jinming Gao; David A Boothman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-03       Impact factor: 12.779

10.  β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.

Authors:  E J Park; K-J Min; T-J Lee; Y H Yoo; Y-S Kim; T K Kwon
Journal:  Cell Death Dis       Date:  2014-05-15       Impact factor: 9.685
View more
  7 in total

1.  Lycorine Inhibits Hypertrophic Scar Formation by Inducing ROS-Mediated Apoptosis.

Authors:  Yunxian Dong; Dongming Lv; Zirui Zhao; Zhongye Xu; Zhicheng Hu; Bing Tang
Journal:  Front Bioeng Biotechnol       Date:  2022-05-24

2.  Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.

Authors:  Mridul Roy; Long Liang; Xiaojuan Xiao; Yuanliang Peng; Yuhao Luo; Weihua Zhou; Ji Zhang; Lugui Qiu; Shuaishuai Zhang; Feng Liu; Mao Ye; Wen Zhou; Jing Liu
Journal:  Theranostics       Date:  2016-09-24       Impact factor: 11.556

3.  Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.

Authors:  Xiezhao Li; Peng Xu; Chongshan Wang; Naijin Xu; Abai Xu; Yawen Xu; Takuya Sadahira; Motoo Araki; Koichiro Wada; Eiji Matsuura; Masami Watanabe; Junxia Zheng; Pinghua Sun; Peng Huang; Yasutomo Nasu; Chunxiao Liu
Journal:  Oncotarget       Date:  2017-03-28

Review 4.  Lycorine: A prospective natural lead for anticancer drug discovery.

Authors:  Mridul Roy; Long Liang; Xiaojuan Xiao; Peifu Feng; Mao Ye; Jing Liu
Journal:  Biomed Pharmacother       Date:  2018-08-14       Impact factor: 6.529

5.  Lycorine inhibits cell proliferation, migration and invasion, and primarily exerts in vitro cytostatic effects in human colorectal cancer via activating the ROS/p38 and AKT signaling pathways.

Authors:  Ping Zhang; Xiaohui Yuan; Tingting Yu; Huakun Huang; Chunmei Yang; Lulu Zhang; Shengdong Yang; Xiaoji Luo; Jinyong Luo
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

Review 6.  Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy.

Authors:  Mao-Bin Meng; Huan-Huan Wang; Yao-Li Cui; Zhi-Qiang Wu; Yang-Yang Shi; Nicholas G Zaorsky; Lei Deng; Zhi-Yong Yuan; You Lu; Ping Wang
Journal:  Oncotarget       Date:  2016-08-30

Review 7.  Current translational potential and underlying molecular mechanisms of necroptosis.

Authors:  Tamás Molnár; Anett Mázló; Vera Tslaf; Attila Gábor Szöllősi; Gabriella Emri; Gábor Koncz
Journal:  Cell Death Dis       Date:  2019-11-12       Impact factor: 8.469
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.